129 studies found for:    "Adenocarcinoma of the appendix"
Show Display Options
Rank Status Study
21 Active, not recruiting Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab;   Drug: cisplatin;   Procedure: quality-of-life assessment
22 Recruiting EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Biological: EGEN-001;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: laboratory biomarker analysis
23 Recruiting Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: veliparib;   Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: carboplatin;   Biological: bevacizumab;   Other: laboratory biomarker analysis
24 Recruiting Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Biological: panitumumab;   Drug: irinotecan hydrochloride;   Drug: fluorouracil;   Drug: leucovorin calcium
25 Completed Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
Conditions: Liver Metastases;   Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Device: irinotecan-eluting beads;   Procedure: hepatic artery embolization
26 Withdrawn Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage I Colon Cancer;   Stage I Rectal Cancer
Interventions: Dietary Supplement: cholecalciferol;   Procedure: biopsy;   Genetic: protein expression analysis;   Other: enzyme-linked immunosorbent assay;   Other: laboratory biomarker analysis;   Genetic: reverse transcriptase-polymerase chain reaction
27 Completed A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IIIA Colon Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Biological: bevacizumab
28 Recruiting Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Cannot Removed by Surgery
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IIIA Colon Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis;   Other: pharmacological study
29 Terminated Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Biological: cetuximab;   Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis;   Other: pharmacological study
30 Completed Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IIIA Colon Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: irinotecan hydrochloride;   Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: fluorouracil;   Procedure: quality-of-life assessment
31 Recruiting Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IIIA Colon Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: irinotecan hydrochloride;   Drug: alisertib
32 Not yet recruiting Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver
Conditions: Liver Metastases;   Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Device: irinotecan-eluting beads;   Procedure: hepatic artery embolization
33 Recruiting Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemotherapy
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IIIA Colon Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Other: cytology specimen collection procedure;   Other: laboratory biomarker analysis;   Other: questionnaire administration
34 Terminated Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
Conditions: Adenocarcinoma of the Colon;   Adenocarcinoma of the Rectum;   Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Drug: irinotecan hydrochloride;   Drug: gefitinib;   Drug: leucovorin calcium;   Drug: fluorouracil
35 Terminated Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: fluorouracil;   Drug: sodium phenylbutyrate;   Drug: indomethacin;   Biological: recombinant interferon gamma
36 Recruiting Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Biological: aflibercept;   Drug: oxaliplatin;   Drug: leucovorin;   Drug: fluorouracil;   Other: Correlative Studies;   Procedure: DCE MRI;   Radiation: f18FDG-PET;   Procedure: PET (positron emission tomography)
37 Recruiting Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
Conditions: Adenocarcinoma of the Lung;   Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Squamous Cell Lung Cancer;   Stage I Colon Cancer;   Stage I Rectal Cancer;   Stage IA Non-small Cell Lung Cancer;   Stage IB Non-small Cell Lung Cancer;   Stage IIA Colon Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Rectal Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer
Interventions: Other: educational intervention;   Other: medical chart review
38 Recruiting Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Adenocarcinoma of the Gallbladder;   Adenocarcinoma of Unknown Primary;   Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Diffuse Adenocarcinoma of the Stomach;   Duct Cell Adenocarcinoma of the Pancreas;   Intestinal Adenocarcinoma of the Stomach;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Carcinoma of Unknown Primary;   Metastatic Extrahepatic Bile Duct Cancer;   Mixed Adenocarcinoma of the Stomach;   Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Newly Diagnosed Carcinoma of Unknown Primary;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage III Pancreatic Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Gallbladder Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Rectal Cancer;   Stage IV Gastric Cancer;   Stage IV Pancreatic Cancer;   Stage IVA Colon Cancer;   Stage IVA Gallbladder Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Gallbladder Cancer;   Stage IVB Rectal Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Interventions: Drug: oxaliplatin;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: fluorouracil;   Other: laboratory biomarker analysis
39 Terminated Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
Conditions: Adenocarcinoma of the Pancreas;   Adenocarcinoma of the Stomach;   BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Ovarian Mucinous Cystadenocarcinoma;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Gastric Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Gastric Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer;   Stage IV Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: veliparib;   Drug: capecitabine;   Drug: oxaliplatin;   Other: pharmacological study;   Other: laboratory biomarker analysis
40 Not yet recruiting Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Ovarian Papillary Serous Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: metformin hydrochloride;   Drug: carboplatin;   Drug: paclitaxel;   Other: laboratory biomarker analysis

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years